XNAS · Healthcare · Biotechnology
Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumor metabolism and signaling pathways.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.62 | -131.45 | -21101.61% | $0 | ❌ Miss | -1.11% | -12.92% | — |
| 2026-03-30 | Q4 2025 | -4.81 | -3.74 | +22.25% | $0 | ✅ Beat | -1.01% | +32.83% | +12.61% |
| 2025-11-14 |
| Q3 2025 |
| -4.11 |
| -3.62 |
| +11.92% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -5.48 | -3.91 | +28.65% | $0 | ✅ Beat | -4.45% | -8.28% | +6.97% |
| 2025-03-28 | Q4 2024 | -0.30 | -0.31 | -3.33% | $0 | ❌ Miss | -22.49% | -43.20% | -24.12% |
| 2024-11-14 | Q3 2024 | -0.31 | -0.29 | +6.45% | $0 | ✅ Beat | -1.86% | +4.74% | -6.51% |
| 2024-08-06 | Q2 2024 | -0.29 | -0.28 | +3.45% | $0 | ✅ Beat | -2.38% | -3.75% | -9.23% |
| 2023-11-07 | Q3 2023 | -0.34 | -0.28 | +17.65% | $0 | ✅ Beat | +9.96% | +6.99% | +2.58% |
Showing last 8 quarters.